Trump lowers expectations of trade deal with Canada as tariff deadline looms
In a post on social media, the president says it will be very hard to make a deal with Canada after Prime Minister Mark Carney on Wednesday announced Ottawa intends to recognize a Palestinian state.
Trump previously sent a letter to Carney threatening to impose 35 per cent tariffs if Canada doesn't make a trade deal by Friday.
The White House has said those duties would not apply to goods compliant with the Canada-U.S.-Mexico Agreement on trade, better known as CUSMA.
While Trump continues to boast about his tariffs on the world, the president's main tool to realign global trade will face a hurdle in court today.
The U.S. Court of Appeals for the Federal Circuit will hear from businesses and states that say Trump's use of a national security statute to implement the duties is beyond his powers as president.
This report by The Canadian Press was first published July 31, 2025.
Kelly Geraldine Malone, The Canadian Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
DuPont Lifts Outlook On Strong Demand In Key Markets
DuPont de Nemours, Inc. (NYSE:DD) stock gained on Tuesday after it beat second-quarter expectations on both earnings and revenue and raised its full-year adjusted earnings outlook, citing strong demand across electronics, healthcare, and water markets. The company reported adjusted earnings per share of $1.12 for the quarter, above the $1.06 analyst estimate. Net sales rose 3% year-over-year to $3.26 billion, topping the $3.23 billion consensus. Sales growth was driven by a 4% increase in volume, partially offset by a 2% decline in price. Organic sales rose 2%. Also Read: GAAP income from continuing operations was $238 million, or 54 cents per share, compared with $176 million, or 40 cents per share, in the same period last year. Adjusted EPS rose 15% from the prior-year quarter, driven by higher segment earnings and a lower tax rate. Operating EBITDA increased 8% to $859 million, with margin expanding 120 basis points to 26.4%. Cash provided by operating activities from continuing operations totaled $381 million. After $116 million in capital expenditures and $168 million in separation-related transaction costs, transaction-adjusted free cash flow reached $433 million. View more earnings on DD ElectronicsCo reported a 6% increase in sales to $1.17 billion, supported by 8% volume growth. Semiconductor Technologies grew in the mid-single digits, while Interconnect Solutions rose in the high-single digits. Segment operating EBITDA rose 14% to $373 million, with margin improving 220 basis points to 31.9%. IndustrialsCo sales increased 1% to $2.09 billion, with 2% volume growth offset by a 1% price decline. Healthcare & Water Technologies grew in the high single digits, while Diversified Industrials declined due to ongoing weakness in construction markets. Segment operating EBITDA rose 3% to $509 million, with margin improving 50 basis points to 24.4%. DuPont ended the quarter with $1.84 billion in cash and $5.33 billion in long-term debt. The company confirmed it remains on schedule for the planned Nov. 1, 2025, spin-off of its Electronics business, Qnity. CEO Lori Koch stated, "Ongoing strength in electronics, healthcare and water end-markets, along with our team's focus on operational execution continued to drive strong earnings growth and cash conversion." Outlook The company raised its full-year 2025 adjusted EPS guidance from a prior range of $4.30–$4.40 to approximately $4.40, exceeding the $4.26 analyst estimate. It also narrowed its full-year net sales forecast from $12.80–$12.90 billion to $12.85 billion, ahead of the $12.78 billion consensus. Guidance now includes a $20 million headwind from tariffs, or 4 cents per share. For the third quarter, DuPont expects adjusted EPS of $1.15 and revenue of $3.32 billion, ahead of analyst estimates of $1.13 and $3.29 billion, respectively. Price Action: At last check Tuesday, DD shares were trading higher by 5.9% to $74.52 premarket. Read Next:Photo by Sundry Photography via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? DUPONT DE NEMOURS (DD): Free Stock Analysis Report This article DuPont Lifts Outlook On Strong Demand In Key Markets originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
AI startup by Columbia graduates raises $7 million to target midsize law firms
By Niket Nishant (Reuters) -August, an AI startup founded by Columbia University alumni and that caters to midsize law firms, said on Tuesday it had raised $7 million in a seed funding round led by venture capital firms NEA and Pear VC. WHY IT MATTERS AI's ability to handle routine, document-heavy tasks is unlocking new efficiencies for lawyers, particularly because the legal field is built on vast volumes of literature such as case law, contracts and filings. By automating time-consuming paperwork, AI platforms such as August are freeing up lawyers to focus on higher-value work. It also helps to cut costs, a crucial benefit for midsize law firms that lack the resources of their deep-pocketed rivals. CONTEXT August was founded in 2023 by Rutvik Rau, Thomas Bueler-Faudree and Joseph Parker, who met at Columbia University. Besides NEA and Pear VC, the startup secured backing from angel investor Gokul Rajaram, Ramp's vice president of product Geoff Charles, OpenAI's head of engineering David Azose and Bain Capital Ventures partner Kevin Zhang. The company is based in New York and currently has a team of 12. It expects to expand the workforce to 25 to 30 by the end of the year, Rau told Reuters in an interview. August operates in a competitive arena dominated by some established players, most notably Harvey, an OpenAI-backed legal AI startup, which caters to elite law firms and big professional services companies. KEY QUOTES "The future is one where AI partners with individuals to be a step further than where the industry is today," Rau said. "We're enabling lawyers to be more productive by eliminating some of the work, so they can actually spend a lot more time working with their clients, understanding their needs and being the strategic value partner for them."
Yahoo
11 minutes ago
- Yahoo
Zero Candida Technologies to Present at the OTCQB Venture Virtual Investor Conference on August 7th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a medical device company developing a SMART, AI-driven FemTech device to revolutionize women's health, today announced that Sophya Galper Komet, CFO, and Dr. Asher Holzer, Founder, will present live at the OTCQB Venture Virtual Investor Conference hosted by on August 7th , 2025. DATE: August 7th TIME: 12:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: August 7 & 8, 2025 This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Company Highlights Demonstrated 99.999% Candida elimination in 3 hours during POC testing, targeting FDA De Novo regulatory pathway Expanding global IP portfolio with patents filed in Europe, the United States, Brazil, and fully granted in South Africa Cross-listed on FSE and OTCQB, including recent DTC eligibility, broadening investor access In active discussions with major hospitals and U.S. pharmaceutical companies to support future clinical trials and commercialization About Zero Candida Technologies Zero Candida Technologies, Inc. is a publicly traded FemTech company pioneering innovative solutions to address unmet needs in women's health. The Company is developing a SMART, tampon-like device that combines artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat Vulvo-Vaginal Candidiasis (VVC) through personalized, at-home care. This condition affects approximately 75% of women worldwide, and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed. With the VVC treatment market projected to exceed US $2B by 2030, Zero Candida is combining hybrid medicine and technology-based diagnostics to improve access for underserved populations and bring gynecology into the 21st century. To learn more, visit About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Zero Candida Technologies, Inc.+1 (647) 874-3767 investors@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@
